We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Boehringer Ingelheim’s Lung Cancer Drug Gilotrif to Get FDA and EMA Review
Boehringer Ingelheim’s Lung Cancer Drug Gilotrif to Get FDA and EMA Review
The FDA and European Medicines Agency have accepted new drug applications for Boehringer Ingelheim’s Gilotrif as a treatment option for patients with advanced squamous cell lung cancer that has progressed after treatment with first-line chemotherapy.